Trius Therapeutics (TSRX +0.7%) says the FDA has designated it's Phase 3 antibiotic candidate,...

|By:, SA News Editor

Trius Therapeutics (TSRX +0.7%) says the FDA has designated it's Phase 3 antibiotic candidate, tedizolid phosphate, as a Qualified Infectious Disease Product for acute bacterial skin and skin structure infections, as well as for hospital-acquired/ventilator-associated bacterial pneumonia. The designation enables the company to benefit from certain incentives for the development of new antibiotics, including priority review and fast-track status.